Revive Therapeutics Ltd (RVVTF)

[ReikoBlack]

That's not how the PR reads.

"To date, the Study has screened approximately 700 subjects."

"In light of Phase 3 clinical studies and FDA approvals of oral antiviral treatments by Pfizer and Merck, it was evident that to ensure a diversified patient population to support future global regulatory submissions for Bucillamine, including the FDA, the Company has decided to fill a part of its patient enrollment quota outside of the U.S. and target Eastern Europe, such as in Turkey"

Well IIRC the US was already at an 800 to 1000 person plan and status this year?

So yes, that is my read, "700 more patients?" in E-Europe, Turkey...

Why would the US FDA accept data from over there? Also begs the question ....

So yes, I think folks miss understood the PR. Vagueness is a pandemic plaque in this world of online BS.... PRs, Advertising...